The Japanese Pharmaceutical Group

Our members employ a total of 3000 people across European HQs that are based here, as well as UK affiliates. However, we have seen roles and functions re-locate to other countries because of Brexit.

We are very proud of the collective efforts of our global companies in the fight against COVID. As of November 2021, JPG member company innovation spans four vaccine candidates, three of which involve novel technology, and four antivirals across the spectrum of patients with asymptomatic, mild to moderate and severe, COVID-19. Our members support five international research collaborations aiming to speed up the development of COVID-19 vaccines and treatments.
JPG’s approach is positive engagement with Government on promoting UK Life Sciences. We have a sub-group of senior R&D colleagues who have UK and global responsibilities.
Our ambition is to partner with Government to optimise Japanese engagement with our ecosystem and reassure HQ concerns following Brexit – our members are ready to move on, but it has undoubtedly cast a shadow.
It is important to stress that our members are accountable for the commercial success of their businesses here in the UK – in this regard there is a need for a fundamental reset on how Government regulates and collaborates with the industry.

The Japanese Pharmaceutical Group (JPG) is the voice of the Japanese life sciences industry in the UK - made up of twelve companies whose global HQs are based in Japan.